drug · small molecule

DYANAVEL XR

updated 3mo ago

by $TRAW Traws Pharma, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for attention deficit hyperactivity disorder and 3 investigational indications.

targets

Sodium-dependent dopamine transporterSodium-dependent noradrenaline transporter

all catalysts(0)

nothing on the calendar yet

Trials studying DYANAVEL XR

phase4EEG Biomarkers for ADHD Stimulant Treatmentnot yet recruitingn=220
phase3MDMA-assisted Massed Prolonged Exposure for PTSDrecruitingn=20
phase1A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Userscompletedn=80
phase2A Phase 2A Trial of DT402 for Autism Spectrum Disorderrecruitingn=20
phase2A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetaminerecruitingn=40
phase3MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSDcompletedn=16
—A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetaminecompletedn=430,000
phase1A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participantscompletedn=76

more trials →

News(0)

no news has mentioned this drug yet

brand

DYANAVEL XR

trade names

Adzenys er, Adzenys xr-odt, Dyanavel xr, Mydayis (mixed salts of a single entity)

generic

AMPHETAMINE

MOA

12.1 Mechanism of Action Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.

indication

1 INDICATIONS AND USAGE DYANAVEL XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older [see Clinical Studies (14) ]. Limitations of Use The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.5) , Use in Specific Populations (8.4) ]. DYANAVEL XR is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older ( 1 ) Limitations of Use The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.5 , 8.4 ).

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 10m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

DYANAVEL XR

updated 3mo ago

by $TRAW Traws Pharma, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for attention deficit hyperactivity disorder and 3 investigational indications.

targets

Sodium-dependent dopamine transporterSodium-dependent noradrenaline transporter

all catalysts(0)

nothing on the calendar yet

Trials studying DYANAVEL XR

phase4EEG Biomarkers for ADHD Stimulant Treatmentnot yet recruitingn=220
phase3MDMA-assisted Massed Prolonged Exposure for PTSDrecruitingn=20
phase1A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Userscompletedn=80
phase2A Phase 2A Trial of DT402 for Autism Spectrum Disorderrecruitingn=20
phase2A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetaminerecruitingn=40
phase3MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSDcompletedn=16
—A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetaminecompletedn=430,000
phase1A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participantscompletedn=76

more trials →

News(0)

no news has mentioned this drug yet

brand

DYANAVEL XR

trade names

Adzenys er, Adzenys xr-odt, Dyanavel xr, Mydayis (mixed salts of a single entity)

generic

AMPHETAMINE

MOA

12.1 Mechanism of Action Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known.

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 10m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

DYANAVEL XR

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying DYANAVEL XR

News(0)

Report a data issue

comments(0)

DYANAVEL XR

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying DYANAVEL XR

News(0)

Report a data issue

comments(0)